Mirum Pharmaceuticals, Inc. (MIRM) Tops Q1 EPS by 17c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Mirum Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
May 5, 2022 8:00 AM EDT- Total revenue for the first quarter of 2022 was $12.9 million including net product revenue for LIVMARLI® (maralixibat) oral solution of $10.9 million.
- Conference call to provide business updates today, May 5 at 5:30 a.m. PT/8:30 a.m. ET
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the first quarter ended March 31, 2022 and provided a business update.
The first quarter was tremendously successful for Mirum. Rapid growth in LIVMARLI revenue means that children suffering from pruritus associated with... More
